Table 3.
Longitudinal changes in markers of β-cell function in DREAM trial: analysis of slopes using mixed-model analysis
| Slope | SE | P | Slope difference | |
|---|---|---|---|---|
| Rosiglitazone versus placebo | ||||
| PI | ||||
| PI/C (adjusted for age) | −0.003 | 0.0005 | 0.25 | 0.0008 |
| PI (adjusted for age, fasting C-peptide) | −1.0524 | 0.1344 | 0.0064 | 0.5308 |
| IGI | ||||
| IGI/HOMA-IR (adjusted for age) | 9.0674 | 1.115 | <0.0001 | −7.0191 |
| IGI (adjusted for age and HOMA-IR) | 5.2814 | 1.3232 | 0.015 | −4.7305 |
| Ramipril versus placebo | ||||
| PI | ||||
| PI/C (adjusted for age) | −0.0028 | 0.0005 | 0.57 | 0.0004 |
| PI (adjusted for age, fasting C-peptide) | −0.7796 | 0.14 | 0.87 | 0.0329 |
| IGI | ||||
| IGI/HOMA-IR (adjusted for age) | 5.2084 | 1.1522 | 0.5 | 1.1206 |
| IGI (adjusted for age and HOMA-IR) | 2.7603 | 1.3517 | 0.73 | 0.6681 |
Analysis in table are based on full data; results essentially unchanged when analysis repeated on subjects with information from all visits.